Expert Forum on Cancer Diagnostics

06 - 07 Nov 2016

Location: Rüschlikon/Zurich, Switzerland

Presentations

 

Sunday, 6 November 2016

18.30

Welcome dinner at Hotel Belvoir in Rüschlikon

 

Monday, 7 November 2016

 

Event moderation: Christoph Nabholz, Head R&D Life&Health, Swiss Re

08.00

Welcome coffee

08.30

Welcome and introduction
Russell Higginbotham, Head Life & Health Products, Member of Reinsurance Executive Committee, Swiss Re

Session

Cancer biomarker technologies

08.35

The future of early molecular cancer diagnostics and preventive immunotherapy
Kenneth Bloom, President, Human Longevity Inc.

09.05

Liquid biopsies and the future of cancer detection
Nicola Aceto, Group Leader Department of Biomedicine, Cancer Metastasis, University of Basel

09.20

Germline Genomics and Liquid Biopsies
Vincent Mooser, Head Lab Department, CHUV, University of Lausanne

09.35

Advanced cancer diagnostics - a global market perspective
Damian Page, Associate Group International Scientific Director, Roche

09.50

Panel discussion moderated by Christoph Nabholz
Kenneth Bloom, President, Human Longevity Inc.
Walter Weder, Professor, Clinic of Thoracic Surgery, University of Zurich
Robert Rubens, Oncologist, Swiss Re
David Lu, Deputy Regional Chief Medical Officer, Swiss Re
Bill Baker, Senior Product Expert EMEA, Swiss Re

10.30

Coffee break

11.00

Workshops
Round 1 starts at 11:00
Round 2 starts at 11:30

Session 1: Breast cancer
Expert: David Miles
Moderator: Beatrice Baldinger
Note taker: Alison McLean

Session 2: Lung cancer
Expert: Damian Page
Moderator: Séverine Rion
Note taker: Urs Widmer

Session 3: Colon cancer
Expert: Andrew Beggs
Moderator: Giselle Abangma
Note taker: Florian Rechfeld

Session 4: Liver cancer
Expert: Vincent Mooser
Moderator: David Lu
Note taker: Rebecca Barwick

12.00

Lunch

Session

Cancer imaging and data analytics

13.15

Big pharma companion diagnostics and the future of preventive immunotherapy for early stage cancers
Luigi Catanzariti, Former Executive Director & Senior Global Program Director Diagnostics, Novartis

13.30

Data-driven medicine revolution in oncology
Pierre Hutter, Chief Scientific Officer and Co-Founder, Sophia Genetics

13.45

Early diagnostics of cancer through advanced imaging technology
Hans Hofstraat, Head Innovation Research, Philips

14.00

Cancer imaging in clinical practice
Thomas Hany, Board certified in radiology and nuclear medicine, Zurich University

14.15

Panel discussion moderated by John Schoonbee, Chief Medical Officer EMEA, Swiss Re
David Miles, Consultant Medical Oncologist, Mount Vernon Cancer Centre
Pierre Hutter, Chief Scientific Officer and Co-Founder, Sophia Genetics
Vincent Mooser, Head Lab Department, CHUV, University of Lausanne
Urs Widmer, Life Guide Medical Officer, Swiss Re
Melanie Slack, Head of Life & Health Products Asia, Swiss Re

15.00

Coffee break

15.30

Workshops
Round 1 starts at 15:30
Round 2 starts at 16:00

Session 1: Liquid biopsy
Expert: Nicola Aceto
Moderator: Urs Widmer
Note taker: Giselle Abangma

Session 2: Imaging technology
Expert: Thomas Hany, Kevin Mader
Moderator: Alison McLean
Note taker: Beatrice Baldinger

Session 3: Cancer profiling
Expert: Pierre Hutter
Moderator: Florian Rechfeld
Note taker: Séverine Rion

Session 4: Regulatory approval of cancer diagnostics
Expert: Encarna Montes Martinez
Moderator: Craig Swatton
Note taker: Sam Ours

16.30

Closing remarks and next steps
Melanie Slack, Head of Life & Health Products Asia, Swiss Re

16.45

End of event

18.00

Optional networking dinner


This event may be photographed, filmed and/ or recorded. A summary of the event, pictures and/or a video of the event in which you may appear may be posted and made available on Swiss Re’s and the Swiss Re Centre for Global Dialogue’s internal and external websites and in printed materials.
 
 
05 Input 2
Liquid biopsies and the future of cancer detection
Nicola Aceto, Group Leader Department of Biomedicine, Cancer Metastasis, University of Basel 


09:20 Input 3
Colorectal cancer profiles determining cancer therapy outcomes
Andrew Birch, Institute of Cancer and Genomic Sciences, University of Birmingham



09:35 Input 4
Advanced cancer diagnostics - a global market perspective

Damian Page, Associate Group International Scientific Director, Roche

Speakers

Gallery

Photos by Natascha Gutknecht

Summary

Critical Illness (CI) insurance is a living benefits product providing indemnity cover for major medical disorders including cancer. For each disease covered the triggers to pay a sum is defined according to clinical diagnostic criteria. With medical progress prompting evolving clinical guidelines, CI definitions become obsolete. The introduction of liquid biopsy might become a disruptor for the diagnosis of cancer with an urgent need to update the current CI cancer definitions and reconsider reserving for in force CI business.

Click here to access the whole summary.